Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.

Orenes-Piñero E, Esteve-Pastor MA, Ruiz-Nodar JM, Quintana-Giner M, Veliz-Martínez A, Tello-Montoliú A, Macías-Villanego MJ, Pernías-Escrig V, Vicente-Ibarra N, Carrillo-Alemán L, Sandín-Rollán M, Martínez JG, Lozano T, Rivera-Caravaca JM, Marín F.

Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.05859-2. [Epub ahead of print]

PMID:
31081301
2.

Alterations of circadian rhythms and their impact on obesity, metabolic syndrome and cardiovascular diseases.

Hernández-García J, Navas-Carrillo D, Orenes-Piñero E.

Crit Rev Food Sci Nutr. 2019 Jan 11:1-10. doi: 10.1080/10408398.2018.1556579. [Epub ahead of print]

PMID:
30633544
3.

Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis.

Carrillo-Aleman L, Marín F, Rivera-Caravaca JM, Vicente-Ibarra N, Candela-Sanchez E, Esteve-Pastor MA, Lozano T, Sandín-Rollan M, Pernias-Escrig V, Macías M, Quintana-Giner M, Veliz A, Orenes-Piñero E, Martínez-Martínez JG, Ruiz-Nodar JM.

Clin Drug Investig. 2019 Mar;39(3):275-283. doi: 10.1007/s40261-018-0736-z.

PMID:
30623372
4.

Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome.

Vicente-Ibarra N, Marín F, Pernías-Escrig V, Sandín-Rollán M, Núñez-Martínez L, Lozano T, Macías-Villaniego MJ, Carrillo-Alemán L, Candela-Sánchez E, Guzmán E, Esteve-Pastor MA, Orenes-Piñero E, Valdés M, Rivera-Caravaca JM, Ruiz-Nodar JM.

Eur J Intern Med. 2019 Mar;61:48-53. doi: 10.1016/j.ejim.2018.12.004. Epub 2018 Dec 20.

PMID:
30579651
5.

Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines.

Candela E, Marín F, Rivera-Caravaca JM, Vicente Ibarra N, Carrillo L, Esteve-Pastor MA, Lozano T, Macías MJ, Pernias V, Sandín M, Orenes-Piñero E, Quintana-Giner M, Hortelano I, Villamía B, Veliz A, Valdés M, Martínez-Martínez JG, Ruiz-Nodar JM.

PLoS One. 2018 Nov 28;13(11):e0208069. doi: 10.1371/journal.pone.0208069. eCollection 2018.

6.

Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year.

Tello-Montoliu A, Ruiz-Nodar JM, Esteve-Pastor MA, Véliz-Martínez A, Orenes-Piñero E, Macías-Villanego MJ, Lozano T, Carrillo-Alemán L, Vicente-Ibarra N, Pernias-Escrig V, Martínez-Martínez JG, Rivera-Caravaca JM, Marín F.

J Clin Pharmacol. 2019 Feb;59(2):295-302. doi: 10.1002/jcph.1318. Epub 2018 Sep 12.

PMID:
30207603
7.

Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.

Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Orenes-Piñero E, Romiti GF, Romanazzi I, Bai Y, Carmo J, Proietti M, Marín F, Lip GYH.

Am J Cardiol. 2018 Sep 1;122(5):785-792. doi: 10.1016/j.amjcard.2018.05.012. Epub 2018 Jun 2.

PMID:
30049460
8.

Impact of gut microbiota on neurological diseases: Diet composition and novel treatments.

Larroya-García A, Navas-Carrillo D, Orenes-Piñero E.

Crit Rev Food Sci Nutr. 2018 Jun 5:1-15. doi: 10.1080/10408398.2018.1484340. [Epub ahead of print]

PMID:
29870270
9.

Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease-4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome.

Rivera-Caravaca JM, Ruiz-Nodar JM, Tello-Montoliu A, Esteve-Pastor MA, Quintana-Giner M, Véliz-Martínez A, Orenes-Piñero E, Romero-Aniorte AI, Vicente-Ibarra N, Pernias-Escrig V, Carrillo-Alemán L, Candela-Sánchez E, Hortelano I, Villamía B, Sandín-Rollán M, Nuñez-Martínez L, Valdés M, Marín F.

J Am Heart Assoc. 2018 Apr 21;7(9). pii: e008725. doi: 10.1161/JAHA.118.008725.

10.

Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality.

Esteve-Pastor MA, Orenes-Piñero E, Roldán V, Lacunza-Ruiz J, Valdés M, Marín F.

Cardiol J. 2018;25(1):151-154. doi: 10.5603/CJ.2018.0014. No abstract available.

11.

Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome.

Orenes-Piñero E, Ruiz-Nodar JM, Esteve-Pastor MA, Quintana-Giner M, Rivera-Caravaca JM, Veliz A, Valdés M, Macías M, Pernias-Escrig V, Vicente-Ibarra N, Carrillo L, Sandín-Rollán M, Candela E, Lozano T, Marín F.

Oncotarget. 2017 Sep 24;8(46):80182-80191. doi: 10.18632/oncotarget.21260. eCollection 2017 Oct 6.

12.

High-resolution proteomics and metabolomics in thyroid cancer: Deciphering novel biomarkers.

Navas-Carrillo D, Rodriguez JM, Montoro-García S, Orenes-Piñero E.

Crit Rev Clin Lab Sci. 2017 Nov - Dec;54(7-8):446-457. doi: 10.1080/10408363.2017.1394266. Epub 2017 Oct 30. Review.

PMID:
29084467
13.

Impact of support networks for breastfeeding: A multicentre study.

Baño-Piñero I, Martínez-Roche ME, Canteras-Jordana M, Carrillo-García C, Orenes-Piñero E.

Women Birth. 2018 Aug;31(4):e239-e244. doi: 10.1016/j.wombi.2017.10.002. Epub 2017 Oct 10.

PMID:
29030022
14.

Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation.

Tello-Montoliu A, Rivera J, Hernández D, Silvente A, Jover E, Rodriguez AI, Quintana M, Romero A, Orenes-Piñero E, Rivera-Caravaca JM, Marín F, Veliz A, Valdés M.

Circ J. 2018 Jan 25;82(2):353-360. doi: 10.1253/circj.CJ-17-0471. Epub 2017 Sep 6.

15.

Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.

Esteve-Pastor MA, Ruíz-Nodar JM, Orenes-Piñero E, Rivera-Caravaca JM, Quintana-Giner M, Véliz-Martínez A, Tello-Montoliu A, PerniasEscrig V, Sandín Rollán M, Vicente-Ibarra N, MacíasVillanego MJ, Candela Sánchez E, Carrillo Alemán L, Lozano T, Valdés M, Marín F.

J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):57-65. doi: 10.1177/1074248417724869. Epub 2017 Aug 9.

PMID:
28789568
16.

Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation.

Orenes-Piñero E, Esteve-Pastor MA, Valdés M, Lip GYH, Marín F.

Drug Discov Today. 2017 Oct;22(10):1565-1571. doi: 10.1016/j.drudis.2017.05.010. Epub 2017 Jul 8. Review.

PMID:
28692826
17.

The future of nutrition: Nutrigenomics and nutrigenetics in obesity and cardiovascular diseases.

Peña-Romero AC, Navas-Carrillo D, Marín F, Orenes-Piñero E.

Crit Rev Food Sci Nutr. 2018;58(17):3030-3041. doi: 10.1080/10408398.2017.1349731. Epub 2017 Aug 24. Review.

PMID:
28678615
18.

Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.

Rivera-Caravaca JM, Ruiz-Nodar JM, Tello-Montoliu A, Esteve-Pastor MA, Veliz-Martínez A, Orenes-Piñero E, Valdés M, Pernias-Escrig V, Sandin-Rollán M, Vicente-Ibarra N, Macías-Villanego MJ, Candela-Sánchez E, Lozano T, Carrillo-Alemán L, Marín F.

Eur J Cardiovasc Nurs. 2017 Dec;16(8):696-703. doi: 10.1177/1474515117710155. Epub 2017 May 16.

PMID:
28509568
19.

Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles.

Navas-Carrillo D, Marín F, Valdés M, Orenes-Piñero E.

Crit Rev Clin Lab Sci. 2017 Jan;54(1):49-58. doi: 10.1080/10408363.2016.1241214. Epub 2016 Dec 26. Review.

PMID:
28013562
20.

A comprehensive insight of novel antioxidant therapies for atrial fibrillation management.

Orenes-Piñero E, Valdés M, Lip GY, Marín F.

Drug Metab Rev. 2015 Aug;47(3):388-400. doi: 10.3109/03602532.2015.1077858. Epub 2015 Aug 26. Review.

PMID:
27412960
21.

miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients.

Orenes-Piñero E, Marín F, Lip GY.

Ann Transl Med. 2016 May;4(10):200. doi: 10.21037/atm.2016.05.27. No abstract available.

22.

Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.

Tello-Montoliu A, Rivera J, Hernández-Romero D, Silvente A, Jover E, Quintana M, Orenes-Piñero E, Hurtado J, Ferreiro JL, Marín F, Valdés M.

Platelets. 2016 Dec;27(8):777-783. Epub 2016 Jun 2.

PMID:
27257022
23.

Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome.

Tortosa-Caparrós E, Navas-Carrillo D, Marín F, Orenes-Piñero E.

Crit Rev Food Sci Nutr. 2017 Nov 2;57(16):3421-3429. doi: 10.1080/10408398.2015.1126549. Review.

PMID:
26745681
24.

Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy.

García-Honrubia A, Hernández-Romero D, Orenes-Piñero E, Romero-Aniorte AI, Climent V, García M, Garrigos-Gómez N, Moro C, Valdés M, Marín F.

Eur J Clin Invest. 2016 Feb;46(2):123-9. doi: 10.1111/eci.12572. Epub 2015 Dec 23.

PMID:
26608562
25.

Controversies surrounding high-protein diet intake: satiating effect and kidney and bone health.

Cuenca-Sánchez M, Navas-Carrillo D, Orenes-Piñero E.

Adv Nutr. 2015 May 15;6(3):260-6. doi: 10.3945/an.114.007716. Print 2015 May. Review.

26.

Novel biomarkers in cardiology: MicroRNAs in atrial fibrillation.

Orenes-Piñero E, Quintana-Giner M, Romero-Aniorte AI, Valdés M, Marín F.

Arch Cardiol Mex. 2015 Jul-Sep;85(3):225-9. doi: 10.1016/j.acmx.2015.01.005. Epub 2015 May 6. Review.

PMID:
25957926
27.

Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State.

Orenes-Piñero E, Pineda J, Roldán V, Hernández-Romero D, Marco P, Tello-Montoliu A, Sogorb F, Valdés M, Lip GY, Marín F.

J Atheroscler Thromb. 2015;22(6):610-7. doi: 10.5551/jat.26161. Epub 2014 Dec 27.

28.

[HDL cholesterol and high-sensitive troponin T as predictive biomarkers of atrial fibrillation after heart surgery].

Lahoz-Tornos Á, Vilchez-Aguilera JA, Hernandez-Romero D, Romero-Aniorte AI, Orenes-Piñero E, Jara-Rubio R, Del Saz-Ortiz A, Arribas-Leal JM, García-Alberola A, Valdés-Chávarri M, Marín-Ortuño F.

Arch Cardiol Mex. 2015 Apr-Jun;85(2):111-7. doi: 10.1016/j.acmx.2014.12.007. Epub 2015 Feb 21. Spanish.

PMID:
25716679
29.

TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy.

Hernández-Romero D, Jover E, Martínez CM, Andreu-Cayuelas JM, Orenes-Piñero E, Romero-Aniorte AI, Casas T, Cánovas S, Montero-Argudo JA, Valdés M, de la Morena G, Marín F.

Eur J Clin Invest. 2015 Feb;45(2):179-86. doi: 10.1111/eci.12394. Epub 2015 Jan 7.

PMID:
25524713
30.

Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Hernández-Romero D, Orenes-Piñero E, García-Honrubia A, Climent V, Romero-Aniorte AI, Martínez CM, García-Bautista M, Martínez M, Feliu E, González J, Cánovas S, Montero-Argudo JA, Valdés M, Marín F.

J Intern Med. 2015 Jul;278(1):50-8. doi: 10.1111/joim.12334. Epub 2015 Jan 5.

31.

Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.

Manzano-Fernández S, Andreu-Cayuelas JM, Marín F, Orenes-Piñero E, Gallego P, Valdés M, Vicente V, Lip GY, Roldán V.

Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):497-504. doi: 10.1016/j.rec.2014.06.026. Epub 2014 Nov 20.

PMID:
25457087
32.

Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.

Navas-Carrillo D, Ríos A, Rodríguez JM, Parrilla P, Orenes-Piñero E.

Biochim Biophys Acta. 2014 Dec;1846(2):468-76. doi: 10.1016/j.bbcan.2014.09.002. Epub 2014 Sep 11. Review.

PMID:
25218916
33.

Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy.

Orenes-Piñero E, Hernández-Romero D, Romero-Aniorte AI, Martínez M, García-Honrubia A, Caballero L, Garrigos-Gómez N, Andreu-Cayuelas JM, González J, Feliu E, Climent V, Nicolás-Ruiz F, De La Morena G, Valdés M, Lip GY, Marín F.

QJM. 2014 Aug;107(8):613-21. doi: 10.1093/qjmed/hcu046. Epub 2014 Mar 5.

PMID:
24599807
34.

High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery.

Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Orenes-Piñero E, Caballero L, Jara-Rubio R, Arribas JM, García-Alberola A, Valdés M, Lip GY, Marín F.

Eur J Cardiothorac Surg. 2014 Apr;45(4):733-8. doi: 10.1093/ejcts/ezt488. Epub 2013 Oct 25.

PMID:
24163361
35.

Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches.

Orenes-Piñero E, Hernández-Romero D, de Torre C, Vilchez JA, Martínez M, Romero-Aniorte AI, Climent V, García-Honrubia A, Valdés M, Marín F.

Ann Med. 2013 Jun;45(4):341-7. doi: 10.3109/07853890.2013.792555. Epub 2013 May 23.

PMID:
23701180
36.

A new process for obtaining hydroxytyrosol using transformed Escherichia coli whole cells with phenol hydroxylase gene from Geobacillus thermoglucosidasius.

Orenes-Piñero E, García-Carmona F, Sánchez-Ferrer A.

Food Chem. 2013 Aug 15;139(1-4):377-83. doi: 10.1016/j.foodchem.2012.12.063. Epub 2013 Feb 1.

PMID:
23561120
37.

Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes.

Montoro-García S, Shantsila E, Tapp LD, López-Cuenca A, Romero AI, Hernández-Romero D, Orenes-Piñero E, Manzano-Fernández S, Valdés M, Marín F, Lip GY.

Atherosclerosis. 2013 Apr;227(2):313-22. doi: 10.1016/j.atherosclerosis.2013.01.028. Epub 2013 Jan 29.

PMID:
23415055
38.

β-Trace protein: from GFR marker to cardiovascular risk predictor.

Orenes-Piñero E, Manzano-Fernández S, López-Cuenca Á, Marín F, Valdés M, Januzzi JL.

Clin J Am Soc Nephrol. 2013 May;8(5):873-81. doi: 10.2215/CJN.08870812. Epub 2013 Jan 18. Review.

39.

Pre and post-operative treatments for prevention of atrial fibrillation after cardiac surgery.

Orenes-Piñero E, Montoro-García S, Banerjee A, Valdés M, Lip GY, Marín F.

Mini Rev Med Chem. 2012 Nov;12(13):1419-31. Review.

PMID:
23106292
40.

Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation.

Hernández-Romero D, Marín F, Roldán V, Peñafiel P, Vilchez JA, Orenes-Piñero E, Giner JA, Valdés M, García-Alberola A.

Pacing Clin Electrophysiol. 2013 Jan;36(1):31-6. doi: 10.1111/pace.12017. Epub 2012 Oct 18.

PMID:
23078110
41.

Role of microRNAs in cardiac remodelling: new insights and future perspectives.

Orenes-Piñero E, Montoro-García S, Patel JV, Valdés M, Marín F, Lip GY.

Int J Cardiol. 2013 Sep 1;167(5):1651-9. doi: 10.1016/j.ijcard.2012.09.120. Epub 2012 Oct 9. Review.

PMID:
23063140
42.

Usefulness of β-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes.

Manzano-Fernández S, López-Cuenca A, Januzzi JL, Parra-Pallares S, Mateo-Martínez A, Sánchez-Martínez M, Pérez-Berbel P, Orenes-Piñero E, Romero-Aniorte AI, Avilés-Plaza F, Valdés-Chavarri M, Marín F.

Am J Cardiol. 2012 Nov 1;110(9):1240-8. doi: 10.1016/j.amjcard.2012.06.027. Epub 2012 Jul 19.

PMID:
22818840
43.

An innovative flow cytometric approach for small-size platelet microparticles: influence of calcium.

Montoro-García S, Shantsila E, Orenes-Piñero E, Lozano ML, Lip GY.

Thromb Haemost. 2012 Aug;108(2):373-83. doi: 10.1160/TH12-02-0120. Epub 2012 Jun 28.

PMID:
22740162
44.

Pharmacological modulation of microparticle release: new strategies for the management of atherothrombotic vascular disorders.

Montoro-García S, Orenes-Piñero E, Marín F, Mariano, Valdés, Lip GY, Shantsila E.

Curr Pharm Des. 2012;18(6):840-9. Review.

PMID:
22288445
45.

High-sensitivity troponin T and copeptin in non-ST acute coronary syndromes: implications for prognosis and role of hsTnT and copeptin in non-STEACS.

Hernández-Romero D, García-Salas JM, López-Cuenca A, Pérez-Berbel P, Puche C, Casas T, Orenes-Piñero E, Manzano-Fernández S, Valdés M, Marín F.

ScientificWorldJournal. 2012;2012:578616. doi: 10.1100/2012/578616. Epub 2012 Jan 4.

46.

KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.

Cebrian V, Fierro M, Orenes-Piñero E, Grau L, Moya P, Ecke T, Alvarez M, Gil M, Algaba F, Bellmunt J, Cordon-Cardo C, Catto J, López-Beltrán A, Sánchez-Carbayo M.

Am J Pathol. 2011 Aug;179(2):540-6. doi: 10.1016/j.ajpath.2011.05.009. Epub 2011 Jun 17.

47.

An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.

Orenes-Piñero E, Hernández-Romero D, Jover E, de la Morena G, Valdés M, Marín F.

Med Chem. 2011 Jul;7(4):275-85. Review.

PMID:
21568880
48.

Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy.

Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F.

J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):521-30. doi: 10.1177/1470320311405247. Epub 2011 Apr 20. Review.

PMID:
21507890
49.

Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene.

Ruppen I, Grau L, Orenes-Piñero E, Ashman K, Gil M, Algaba F, Bellmunt J, Sánchez-Carbayo M.

Mol Cell Proteomics. 2010 Oct;9(10):2276-91. doi: 10.1074/mcp.M900255-MCP200. Epub 2010 Feb 5.

50.

Serum and tissue profiling in bladder cancer combining protein and tissue arrays.

Orenes-Piñero E, Barderas R, Rico D, Casal JI, Gonzalez-Pisano D, Navajo J, Algaba F, Piulats JM, Sanchez-Carbayo M.

J Proteome Res. 2010 Jan;9(1):164-73. doi: 10.1021/pr900273u.

PMID:
19883059

Supplemental Content

Loading ...
Support Center